Trial Profile

A phase I study Afatinib in Combination of Osimertinib in patients with Relapsed Non-Small Cell Lung Cancer after failure of prior Osimertinib

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary) ; Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions

Most Recent Events

13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer
01 Mar 2021 Status changed from not yet recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com